Base Editing Corrects Common Haemophilia A...
CMN Briefs
May. 9, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
SeQure Dx
Company type: CRO
Main focus: Genomic assays for on-target and off-target analysis
Company stage: Actively providing services
Diseases: None
Genome-editing tool: N/A
Funding stage: 17.5 M (Series A)
Location: Waltham, Massachusetts USA
Website: https://www.sequre-dx.com
Pipeline: N/A
Partners:
Sequre Dx provides services for the identification of off-target gene edits, supporting customers at different stages from discovery to pre-clinical, manufacturing stage, and product commercialisation. It uses a proprietary platform to nominate all possible off-target sites using a custom genomic database representative of the intent-to-treat population. Confirmation of off-target edits is conducted in representative in vitro, in vivo, or ex vivo environments.
